Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

343
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
343
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

398
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
398
Angina IV: Management01:26

Angina IV: Management

493
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
493

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proteome landscape of B-cell malignancies identifies mantle cell lymphoma protein signature.

bioRxiv : the preprint server for biology·2026
Same author

Persistence of PET scan positivity after chemoimmunotherapy for DLBCL.

Blood advances·2026
Same author

Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial.

Annals of hematology·2026
Same author

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Blood advances·2026
Same author

Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma.

Nature communications·2025
Same author

Cooperative role of distinctive TP53 and PTEN combined loss in the peripheral T cell lymphoma-GATA3 molecular subgroup.

Science advances·2025

Related Experiment Video

Updated: May 3, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

13.6K

Angioimmunoblastic T-cell lymphoma management.

Kailash Mosalpuria1, R Gregory Bociek1, Julie M Vose1

  • 1UNMC Oncology/Hematology Division, Nebraska Medical Center, Omaha, NE.

Seminars in Hematology
|January 29, 2014
PubMed
Summary

Angioimmunoblastic T-cell lymphoma (AITL) is a common peripheral T-cell lymphoma (PTCL) with poor treatment responses. This review covers AITL

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Angioimmunoblastic T-cell lymphoma (AITL) is a frequent subtype of peripheral T-cell lymphoma (PTCL).
  • AITL presents with generalized lymphadenopathy, extranodal involvement, and immune dysregulation, leading to infections as a common cause of mortality.
  • Current first-line therapies for AITL have shown limited efficacy.

Purpose of the Study:

  • To review the clinical features, pathobiology, and prognostic models of AITL.
  • To discuss current standard therapies and emerging therapeutic agents for AITL.
  • To explore future treatment implications for AITL.

Main Methods:

  • Literature review of clinical features, pathobiology, and treatment strategies for AITL.
  • Analysis of recent advances in understanding AITL's clonal T-cell disorder and microenvironment effects.

More Related Videos

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

16.3K
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.8K

Related Experiment Videos

Last Updated: May 3, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

13.6K
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

16.3K
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.8K
  • Synthesis of data on standard and novel therapeutic agents.

    • Main Results:

    • AITL is characterized by significant immune dysregulation and poor responses to initial treatments.
    • Advances in pathobiology reveal AITL as a clonal T-cell disorder impacting B cells.
    • Prognostic models and newer agents offer potential for improved outcomes.

    Conclusions:

    • Understanding AITL's pathobiology is crucial for developing effective treatments.
    • Novel therapeutic agents show promise for improving outcomes in AITL.
    • Further research into AITL's implications for future therapies is warranted.